Literature DB >> 2454190

Triggering CD 28 molecules synergize with CD 2 (T 11.1 and T 11.2)-mediated T cell activation.

A Pierrès1, M Lopez, C Cerdan, J Nunes, D Olive, C Mawas.   

Abstract

Pairs of monoclonal antibodies (mAb) defining epitopes T 11.1 and T 11.2 on the CD 2 molecule are mitogenic for purified human T cells in the presence of a submitogenic dose of 12-O-tetradecanoylphorbol 13-acetate (TPA). Anti-CD 28 mAb can substitute for the action of TPA in the anti-CD 2-induced proliferative response of resting T cells, whereas each signal alone is unable to mediate this effect. Co-stimulation by anti-CD 2 plus anti-CD 28 mAb is monocyte independent and besides resting T cells also induces strong proliferation of thymocytes and pre-activated T cells. Modulation of the CD 3-T cell receptor complex does not inhibit the co-stimulatory effects of anti-CD 2 plus anti-CD 28 mAb. The effect is largely dependent on endogenously produced interleukin 2, since the response is strongly inhibited in the presence of mAb against the 55-kDa interleukin 2 receptor chain.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454190     DOI: 10.1002/eji.1830180505

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

1.  CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes.

Authors:  M Azuma; M Cayabyab; D Buck; J H Phillips; L L Lanier
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

2.  CTLA4-Ig inhibits allergic airway inflammation by a novel CD28-independent, nitric oxide synthase-dependent mechanism.

Authors:  Christine M Deppong; Amit Parulekar; Jonathan S Boomer; Traci L Bricker; Jonathan M Green
Journal:  Eur J Immunol       Date:  2010-07       Impact factor: 5.532

3.  Regulation of T-cell differentiation by CD2 and CD28 accessory molecules.

Authors:  R de Jong; P Stokkers; E Lamme; J M Kool; F Borst; M Brouwer; F Miedema; R A van Lier
Journal:  Immunology       Date:  1991-10       Impact factor: 7.397

4.  Human CD28 and CTLA-4 Ig superfamily genes are located on chromosome 2 at bands q33-q34.

Authors:  M Lafage-Pochitaloff; R Costello; D Couez; J Simonetti; P Mannoni; C Mawas; D Olive
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

5.  T lymphocyte anergy during acute infectious mononucleosis is restricted to the clonotypic receptor activation pathway.

Authors:  M Pérez-Blas; J R Regueiro; J R Ruiz-Contreras; A Arnaiz-Villena
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

6.  Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80).

Authors:  R S McHugh; S N Ahmed; Y C Wang; K W Sell; P Selvaraj
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

7.  Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.

Authors:  Sophie Reuse; Miriam Calao; Kabamba Kabeya; Allan Guiguen; Jean-Stéphane Gatot; Vincent Quivy; Caroline Vanhulle; Aurélia Lamine; Dolores Vaira; Dominique Demonte; Valérie Martinelli; Emmanuelle Veithen; Thomas Cherrier; Véronique Avettand; Solène Poutrel; Jacques Piette; Yvan de Launoit; Michel Moutschen; Arsène Burny; Christine Rouzioux; Stéphane De Wit; Georges Herbein; Olivier Rohr; Yves Collette; Olivier Lambotte; Nathan Clumeck; Carine Van Lint
Journal:  PLoS One       Date:  2009-06-30       Impact factor: 3.240

8.  Signalling through CD28 T-cell activation pathway involves an inositol phospholipid-specific phospholipase C activity.

Authors:  J Nunes; S Klasen; M D Franco; C Lipcey; C Mawas; M Bagnasco; D Olive
Journal:  Biochem J       Date:  1993-08-01       Impact factor: 3.857

9.  Age-related defects in CD2 receptor-induced activation in human T-cell subsets.

Authors:  I Beckman; K Shepherd; F Firgaira; M Ahern
Journal:  Immunology       Date:  1995-12       Impact factor: 7.397

10.  Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1.

Authors:  Sophie Bouchat; Nadège Delacourt; Anna Kula; Gilles Darcis; Benoit Van Driessche; Francis Corazza; Jean-Stéphane Gatot; Adeline Melard; Caroline Vanhulle; Kabamba Kabeya; Marion Pardons; Véronique Avettand-Fenoel; Nathan Clumeck; Stéphane De Wit; Olivier Rohr; Christine Rouzioux; Carine Van Lint
Journal:  EMBO Mol Med       Date:  2016-02-01       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.